Modality
Gene Editing
MOA
STINGag
Target
IL-13
Pathway
Complement
RCCHemophilia APTSD
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Feb 2030
Phase 2Current
NCT07182219
1,556 pts·RCC
2025-10→2029-04·Recruiting
NCT05773333
1,708 pts·Hemophilia A
2020-11→2030-02·Not yet recruiting
3,264 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-04-103.0y awayPh3 Readout· RCC
2030-02-153.9y awayPh3 Readout· Hemophilia A
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Not yet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2029-04-10 · 3.0y away
RCC
Ph3 Readout
2030-02-15 · 3.9y away
Hemophilia A
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07182219 | Phase 2/3 | RCC | Recruiting | 1556 | HAM-D |
| NCT05773333 | Phase 2/3 | Hemophilia A | Not yet recr... | 1708 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |